Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges | Zendy

Yousef Roosta | Zendy; Farhad Behzadi | Zendy; Elham Askari | Zendy; Mortaza Raeisi | Zendy; Amin Danandeh Mehr | Zendy; Masoud NouriVaskeh | Zendy

Open Access

Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges

Author(s) -

Yousef Roosta,

Farhad Behzadi,

Elham Askari,

Mortaza Raeisi,

Amin Danandeh Mehr,

Masoud NouriVaskeh

Publication year - 2021

Publication title -

leukemia research reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.392

H-Index - 12

ISSN - 2213-0489

DOI - 10.1016/j.lrr.2021.100239

Subject(s) - medicine , chronic lymphocytic leukemia , covid-19 , epidemiology , intensive care medicine , disease , leukemia , pathology , infectious disease (medical specialty) , outbreak

A comprehensive review of the literature on chronic lymphocytic leukemia (CLL) patients and recommendations regarding the evaluation and treatment of these patients was conducted. The overall prevalence of CLL and COVID-19 concurrence was found to be 0.6% (95%CI: 0.5% to 0.7%). Diagnostic interaction between CLL and COVID-19 remains a major challenge. Also, CLL patients have a lower rate of anti-SARS-CoV-2 IgG development. Evidences show the unacceptable therapeutic outcome in these patients. Although the CLL-COVID-19 occurrence is associated with adverse clinical consequences, no general and standard agreement has yet been presented for the management and treatment of this disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research